Effect of study setting on anticoagulation control: A systematic review and metaregression

Chest

Volumn 129, Issue 5, 2006, Pages 1155-1166

  Van Walraven, Carl ^a   Jennings, Alison ^a   Oake, Natalie ^a   Fergusson, Dean ^a   Forster, Alan J ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Anticoagulation; Deep venous thrombosis; Pulmonary embolism

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; DICOUMAROL; ETHYL BISCOUMACETATE; PHENPROCOUMON; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COMMUNITY CARE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SELF CARE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

EID: 33646468354     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.5.1155     Document Type: Article

References (97)

1. Houston DS, Black C, Metge S, et al. The epidemiology of warfarin use in the population of Manitoba, Canada [abstract]. Thromb Haemost 2001; 86(suppl):195
2. Linkins LA, Choi PT, Douketis JD, Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139:893-900
3. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126:1938-1945
4. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11-17
5. Samsa GP, Matchar DB, Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000; 9:283-292
6. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120:526-528
7. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135:393-400
8. Visser LE, Penning-van Beest FJ, Wilson JH, et al. Overanticoagulation associated with combined use of lactulose and coumarin anticoagulants. Br J Clin Pharmacol 2004; 57:522-524
9. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121:676-683
10. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279:657-662
11. Penning-van Beest FJ, van Meegen E, Rosendaal FR, et al. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001; 86:569-574
12. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279:657-662
13. Visser LE, Bleumink GS, Trienekens PH, et al. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol 2004; 127:85-89
14. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135:393-400
15. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719
16. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698
17. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial, Ann Intern Med 2000; 133:687-695
18. Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J 1982; 103:445-446
19. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. Arch Intern Med 1984; 144:1966-1968
20. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study; Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118:511-520
21. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT); Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348:423-428
22. Wilson SJ-A, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Can Med Assoc J 2003; 169:293-298
23. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362:1691-1698
24. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994; 154:1945-1953
25. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):204S-233S
26. Azar AJ, Deckers JW, Rosendaal FR, et al. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemost 1994; 72:347-351
27. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119(suppl):228-238
28. Schmitt L, Speckman J, Ansell J, et al. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003; 15:213-216
29. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000; 356:97-102
30. Chen MK. A comment on continuity of care: does it contribute to quality of care. Med Care 1980; 18:969-970
31. Hirsch RP, Riegelman RK. Nominal dependent variables. In: Statistical first aid: interpretation of health research data. Oxford, UK: Blackwell Scientific Publications, 1992; 92-104
32. Holm T, Lassen JF, Husted SE, et al. The quality of routine oral anticoagulant therapy in a large geographical area: a survey of 310,300 inhabitants, Dan Med Bull 2002; 49:252-255
33. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91:472-477
34. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133-1138
35. Kalra L, Yu G, Perez I, et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320:1236-1239
36. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685-2695
37. Frost L, Johnsen SP, Pedersen L, et al. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med 2002; 252:64-69
38. Caro JJ, Flegel KM, Orejuela ME, et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. Can Med Assoc J 1999; 161:493-497
39. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, et al. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003; 163:2639-2646
40. Sidhu P, O'Kane HO, Sidhu P, et al. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 2001; 72:1523-1527
41. Hasenkam JM, Kimose HH, Knudsen L, et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997; 11:935-942
42. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84:805-810
43. Christensen TD, Andersen NT, Attermann J, et al. Mechanical heart valve patients can manage oral anticoagulant therapy themselves. Eur J Cardiothorac Surg 2003; 23:292-298
44. Holm T, Lassen JF, Husted SE, et al. A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med 2002; 252:322-331
45. Holm T, Deutch S, Lassen JF, et al. Prospective evaluation of the quality of oral anticoagulation management in an outpatient clinic and in general practices. Thromb Res 2002; 105:103-108
46. Baggio D, Madore F, Lalonde G, et al. Oral anticoagulant therapy for heart disease: results in actual cardiology practice. Can J Cardiol 2000; 16:153-161
47. Barcellona D, Contu P, Marongiu F, et al. Patient education and oral anticoagulant therapy. Haematologica 2002; 87:1081-1086
48. Taylor FC, Gaminara E, Cohen H, et al. Evaluation of a nurse specialist anticoagulant service. Clin Lab Haematol 1997; 19:267-272
49. van Dongen CJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005; 3:939-942
50. Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome; a retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:513-519
51. Hutten BA, Prins MH, Redekop WK, et al. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost 1999; 82:1260-1263
52. Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study; Atrial Fibrillation Aspirin arid Anticoagulation. Arch Intern Med 1999; 159:1322-1328
53. Kearon C, Gent M, Hirsh J, et al. A Comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-907
54. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158:1641-1647
55. Abdelhafiz AH, Wheeldon NM. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther 2004; 26:1470-1478
56. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85:418-422
57. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96:1816-1819
58. Poli D, Antonucci E, Lombardi A, et al. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagul Fibrinolysis 2003; 14:269-275
59. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160:967-973
60. Menendez-Jandula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005; 142:1-10
61. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349:631-639
62. Fitzmaurice DA, Murray ET, Gee KM, et al. Does the Birmingham model of oral anticoagulation management in primary care work outside trial conditions? Br J Gen Pract 2001; 51:828-829
63. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36:200-204
64. Milligan PE, Banet GA, Waterman AD, et al. Substitution of generic warfarin for Coumadin in an HMO setting. Ann Pharmacother 2002; 36:764-768
65. Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26:1149-1159
66. Poli D, Chiarugi L, Capanni M, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis 2002; 13:297-300
67. Waterman AD, Milligan PE, Bayer L, et al. Effect of warfarin nonadherence on control of the international normalized ratio. Am J Health Syst Pharm 2004; 61:1258-1264
68. Bull K, Spiegelhalter DJ. Survival analysis in observational studies. Stat Med 1997; 16:1041-1074
69. Mitra R, Marciello MA, Brain C, et al. Efficacy of computer-aided dosing of warfarin among patients in a rehabilitation hospital. Am J Phys Med Rehabil 2005; 84:423-427
70. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127:1515-1522
71. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study. Ann Pharmacother 2005; 39:446-451
72. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293:690-698
73. Sunderji R, Gin K, Shalansky K, et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. Can J Cardiol 2004; 20:1117-1123
74. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126:557-564
75. Chan TY, Miu KY, Chan TY, et al. Hemorrhagic complications of anticoagulant therapy in Chinese patients. J Chin Med Assoc 2004; 67:55-62
76. Matchar DB. Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. Card Electrophysiol Rev 2003; 7:379-381
77. van Geest-Daalderop JH, Hutten BA, Sturk A, et al. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. J Thromb Thrombolysis 2003; 15:197-203
78. Laporte S, Quenet S, Buchmuller-Cordier A, et al. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 2003; 89:458-467
79. Tassies D, Freire C, Pijoan J, et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87:1185-1191
80. Fitzmaurice DA, Murray ET, Gee KM, et al. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol 2002; 55:845-849
81. Evans A, Perez I, Yu G, et al. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 2001; 32:2828-2832
82. McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161:2458-2463
83. Evans A, Perez I, Yu G, et al. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke 2000; 31:2106-2111
84. Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63:192-196
85. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158:1513-1521
86. Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997; 157:978-984
87. Bona RD, Sivjee KY, Hickey AD, et al. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995; 74:1055-1058
88. Van Deelen BAJ, van den Bemt PMLA, Egberts TCG, et al. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging 2005; 22:353-360
89. Goldberg Y, Meytes D, Shabtai E, et al. Monitoring oral anticoagulant therapy by telephone communication. Blood Coagul Fibrinolysis 2005; 16:227-230
90. Marco F, Sedano C, Bermudez A, et al. A prospective controlled study of a computer-assisted acenocoumarol dosage program. Pathophysiol Haemost Thromb 2003; 33:59-63
91. Witt DM, Tillman DJ, Evans CM, et al. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program. Pharmacotherapy 2003; 23:360-368
92. Vadher BD, Patterson DL, Leaning M, et al. Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians. Clin Lab Haematol 1997; 19:203-207
93. Vadher B, Patterson DL, Leaning M, et al. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. BMJ 1997; 314:1252-1256
94. Johnson SG, Witt DM, Delate T, et al. An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy. J Thromb Thrombolysis 2005; 19:209-212
95. You JHS, Chan FWH, Wong RSM, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59:582-587
96. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18:349-355
97. Goudie BM, Danskin KL, Al-Agilly SS, et al. Near patient monitoring of anticoagulant therapy in general practice [letter]. Scot Med J 2004; 49:70